


First-line treatment for metastatic squamous cell lung cancer (mSCLC, age 60)

An otherwise healthy 60-year-old patient presents with low tumor burden, asymptomatic, metastatic PWT squamous cell carcinoma of the lung. What is your preferred first-line treatment regimen?



EDITOR'S COMMENTS

For quite some time our survey and polling data showed that patients with mSCLC almost always received 1 of 2 regimens — carboplatin with either gemcitabine (Dr Wakelee's current choice) or paclitaxel (Dr Ramalingam's selection). However, following data presented by Dr Mark Socinski and others revealing a potential increase in response rate with nanoparticle albumin-bound (*nab*) paclitaxel in this patient subset, it appears that oncologists now turn to that drug in combination with a platinum almost as frequently as they do the others.

SELECT REFERENCES WITH LINKS

Einhorn LH. **First-line chemotherapy for non-small-cell lung cancer: Is there a superior regimen based on histology?** *J Clin Oncol* 2008;26(21):3485-6. [Abstract](#)

Scagliotti GV et al. **Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.** *J Clin Oncol* 2008;26(21):3543-51. [Abstract](#)

Socinski MA et al. **Weekly *nab*-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial.** *J Clin Oncol* 2012;30(17):2055-62. [Abstract](#)